Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Jacobson

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Clinics in Liver Disease|August 27, 2011
Telaprevir user's guideAnnMarie Liapakis, Ira Jacobson
Pharmacogenomics|February 9, 2010
Pharmacogenetics of hepatitis C therapyAnnmarie Liapakis, Ira Jacobson
Annals of Internal Medicine|November 17, 2005
Cost-effectiveness in hepatitis BGil Weitzman, Ira Jacobson
Nature Clinical Practice. Gastroenterology & Hepatology|February 3, 2007
Future therapies for hepatitis C: where do we go from here?Samuel Sigal, Ira Jacobson
Liver International : Official Journal of the International Association for the Study of the Liver|January 4, 2012
Telaprevir user's guideAnn Marie Liapakis, Ira Jacobson
Seminars in Liver Disease|December 23, 2011
The conundrum of relapse in STAT-C therapy: does HCV play the Red Queen or Rip Van Winkle?Robert Ralston, Ira Jacobson, Margaret Scull
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 16, 2020
Hepatitis E Virus Infection in the United States: Current Understanding of the Prevalence and Significance in the Liver Transplant Patient Population and Proposed Diagnostic and Treatment StrategiesMaureen Whitsett, David M Feldman, Ira Jacobson
Antiviral Therapy|March 10, 2012
Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymeraseJean-Michel Pawlotsky, Isabel Najera, Ira Jacobson
Current Gastroenterology Reports|February 5, 2002
The HCV and HIV coinfected patient: what have we learned about pathophysiology?Andrew H Talal, P Wilfredo Canchis, Ira Jacobson
Gut|April 17, 2012
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectivesChristoph Welsch, Arun Jesudian, Stefan Zeuzem, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Clinics in Liver Disease|August 27, 2011
Telaprevir user's guideAnnMarie Liapakis, Ira Jacobson
Pharmacogenomics|February 9, 2010
Pharmacogenetics of hepatitis C therapyAnnmarie Liapakis, Ira Jacobson
Annals of Internal Medicine|November 17, 2005
Cost-effectiveness in hepatitis BGil Weitzman, Ira Jacobson
Nature Clinical Practice. Gastroenterology & Hepatology|February 3, 2007
Future therapies for hepatitis C: where do we go from here?Samuel Sigal, Ira Jacobson
Liver International : Official Journal of the International Association for the Study of the Liver|January 4, 2012
Telaprevir user's guideAnn Marie Liapakis, Ira Jacobson
Seminars in Liver Disease|December 23, 2011
The conundrum of relapse in STAT-C therapy: does HCV play the Red Queen or Rip Van Winkle?Robert Ralston, Ira Jacobson, Margaret Scull
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 16, 2020
Hepatitis E Virus Infection in the United States: Current Understanding of the Prevalence and Significance in the Liver Transplant Patient Population and Proposed Diagnostic and Treatment StrategiesMaureen Whitsett, David M Feldman, Ira Jacobson
Antiviral Therapy|March 10, 2012
Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymeraseJean-Michel Pawlotsky, Isabel Najera, Ira Jacobson
Current Gastroenterology Reports|February 5, 2002
The HCV and HIV coinfected patient: what have we learned about pathophysiology?Andrew H Talal, P Wilfredo Canchis, Ira Jacobson
Gut|April 17, 2012
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectivesChristoph Welsch, Arun Jesudian, Stefan Zeuzem, et al.
Pageof 5